MPM BioImpact
A Boston biotech investor, formerly MPM Capital, that builds and funds companies and runs an Oncology Impact Fund that donates part of its profits to cancer research. It built Aktis Oncology and backs Cullinan Oncology and Tizona.
Overview
MPM BioImpact (formerly MPM Capital) is based at 399 Boylston Street, Boston, and claims '30+ Years of Biotech Investing', '60 FDA-approved drugs' and '120+ M&A and IPO events' on its homepage. Its portfolio page says its 'current strategy that focuses on company building began in 2010'; it invests in private and public companies and its trademarks include the Oncology Impact Fund (OIF), which pairs oncology venture investing with philanthropic donations. The homepage says 'We built Aktis Oncology to realize the transformative potential of alpha radio-pharmaceuticals', describing miniprotein actinium conjugates for solid tumours, and 'We built Orna Therapeutics' (circular RNA, acquired by Lilly in 2026). The portfolio page lists Aktis, Cullinan Oncology, Tizona Therapeutics, Frontier Medicines and Umoja Biopharma among others; the news page carries Aktis first-in-human dosimetry data and J&J's acquisition of Firefly Bio.
Portfolio in OnCo (2)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Firefly Bio South San Francisco, CA, US | Acquired | biotech | Acquisition 2026, $1B | |
| Photys Therapeutics Boston, MA, US | Startup | biotech | Series A 2022, $75M |
Notes
top- Founding year of MPM Capital not stated on fetched pages; omitted. Aktis, Frontier Medicines, Umoja and Orna are already in the graph.
Pages like this
not linked directly; found by shared links- CompanyOmega Funds
Shares Photys Therapeutics and the tag vc.
- CompanyLongwood Fund
Shares Photys Therapeutics and the tag vc.
- CompanyVersant Ventures
Shares Firefly Bio and the tag vc.